Literature DB >> 21055500

Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans.

Brian A Crowe1, Peter Brühl, Marijan Gerencer, Michael G Schwendinger, Andreas Pilz, Otfried Kistner, Katrin Koelling-Schlebusch, Gerald Aichinger, Julia Singer, Markus Zeitlinger, Markus Müller, Hartmut Ehrlich, P Noel Barrett.   

Abstract

In the present study the homologous and heterologous type and subtype specific cellular immune response induced by a wild type inactivated whole virus H5N1 Influenza (A/Vietnam/1203/2004) vaccine was evaluated. Two immunizations with the Vero cell derived H5N1 influenza vaccine on Day 0 and Day 21 induced significant H5N1 vaccine specific and H5 haemagglutinin specific clade and cross-clade reactive CD4(+) T cell responses, which were maintained at significant levels for at least 6 months. The H5N1 vaccine specific response cross-reacted with the H1N1, but not with H3N2 or B seasonal Influenza strains. The vaccine significantly increased the number of H5N1 specific and H5 haemagglutinin specific memory B cells, 6 months after the primary immunization, however no H1N1 specific cross-reactivity was observed. Importantly, the inactivated whole virus H5N1 vaccine was just as effective in inducing CD4(+) T cell and memory B cell response in the elderly (60 years or over) as in the adult population (18-59 years).
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21055500     DOI: 10.1016/j.vaccine.2010.10.065

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

Review 1.  H5N1 vaccines in humans.

Authors:  Mariana Baz; Catherine J Luke; Xing Cheng; Hong Jin; Kanta Subbarao
Journal:  Virus Res       Date:  2013-05-28       Impact factor: 3.303

Review 2.  Cell culture-based influenza vaccines: A necessary and indispensable investment for the future.

Authors:  Nagendra R Hegde
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patients.

Authors:  Maikel V W van der Velden; Alexander Geisberger; Thomas Dvorak; Daniel Portsmouth; Richard Fritz; Brian A Crowe; Wolfgang Herr; Eva Distler; Eva M Wagner; Markus Zeitlinger; Robert Sauermann; Christoph Stephan; Hartmut J Ehrlich; P Noel Barrett; Gerald Aichinger
Journal:  Clin Vaccine Immunol       Date:  2014-04-16

4.  Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes.

Authors:  Shital M Patel; Robert L Atmar; Hana M El Sahly; Kuo Guo; Heather Hill; Wendy A Keitel
Journal:  J Infect Dis       Date:  2012-08-13       Impact factor: 5.226

Review 5.  A/H5N1 prepandemic influenza vaccine (whole virion, vero cell-derived, inactivated) [Vepacel®].

Authors:  Greg L Plosker
Journal:  Drugs       Date:  2012-07-30       Impact factor: 9.546

6.  Refining the approach to vaccines against influenza A viruses with pandemic potential.

Authors:  Rita Czako; Kanta Subbarao
Journal:  Future Virol       Date:  2015       Impact factor: 1.831

7.  Identification of H5N1-specific T-cell responses in a high-risk cohort in vietnam indicates the existence of potential asymptomatic infections.

Authors:  Timothy J Powell; Annette Fox; Yanchun Peng; Le Thi Quynh Mai; Vu T K Lien; Nguyen L K Hang; Lili Wang; Laurel Y-H Lee; Cameron P Simmons; Andrew J McMichael; Jeremy J Farrar; Brigitte A Askonas; Tran Nhu Duong; Pham Quang Thai; Nguyen Thi Thu Yen; Sarah L Rowland-Jones; Nguyen Tran Hien; Peter Horby; Tao Dong
Journal:  J Infect Dis       Date:  2011-11-11       Impact factor: 5.226

Review 8.  Immunological assessment of influenza vaccines and immune correlates of protection.

Authors:  Adrian Reber; Jacqueline Katz
Journal:  Expert Rev Vaccines       Date:  2013-05       Impact factor: 5.217

9.  Long-term vaccine-induced heterologous protection against H5N1 influenza viruses in the ferret model.

Authors:  Mariette F Ducatez; Ashley Webb; Jeri-Carol Crumpton; Richard J Webby
Journal:  Influenza Other Respir Viruses       Date:  2012-08-16       Impact factor: 4.380

10.  Protection against H5N1 highly pathogenic avian and pandemic (H1N1) 2009 influenza virus infection in cynomolgus monkeys by an inactivated H5N1 whole particle vaccine.

Authors:  Misako Nakayama; Shintaro Shichinohe; Yasushi Itoh; Hirohito Ishigaki; Mitsutaka Kitano; Masahiko Arikata; Van Loi Pham; Hideaki Ishida; Naoko Kitagawa; Masatoshi Okamatsu; Yoshihiro Sakoda; Takaya Ichikawa; Hideaki Tsuchiya; Shinichiro Nakamura; Quynh Mai Le; Mutsumi Ito; Yoshihiro Kawaoka; Hiroshi Kida; Kazumasa Ogasawara
Journal:  PLoS One       Date:  2013-12-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.